secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001213900-25-003026
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara reports positive TARA-002 NMIBC data; expects key milestones in 2025; cash runway into 2027
--------------------------------------------------------------------------------

- TARA-002 in NMIBC: 72% CR at six months, 70% at any time; 100% maintained CR from 3 to 6 months; no Grade 2+ TRAEs.
- Expects 12-month evaluable data mid-2025 and futility analysis of ~25 BCG-unresponsive patients by end 2025.
- Expects to start THRIVE-3 registrational trial of IV Choline Chloride in 1H 2025; FDA Fast Track granted.
- TARA-002 in LMs: initial results from additional STARBORN-1 cohorts expected by end of 1H 2025.
- Cash of $81.5M plus ~$100M gross from December offering (including partial option exercise) funds operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/0001213900-25-003026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea0227457-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-003026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer